Background. We assessed the efficacy, effectiveness and safety of artemether-lumefantrine, which is the most widely used artemisinin-based combination therapy in Africa, against Plasmodium falciparum malaria during an extended follow-up period after initial and repeated treatment.
Tanzania introduced it as the official first-line treatment in 2006 [5] .
The day 7 blood lumefantrine concentration profile has been shown to be a main determinant of artemether-lumefantrine efficacy [6] [7] [8] . Lumefantrine absorption largely depends on concomitant fatty food-intake [7] [8] [9] . The fat content of most African diets appears to be adequate to ensure high efficacy [10, 11] . However, the complex dose regimen might compromise adherence, and, indeed, day 7 lumefantrine concentrations have been shown to be significantly lower in patients with unsupervised intake than in those with supervised intake [12] [13] [14] . Despite this, unsupervised treatment appears to be effective [13] [14] [15] ; however, importantly, most studies have only a 28-day follow-up period, which is not sufficient to detect a substantial portion of patients who experience treatment failure or recrudescence, considering the slow lumefantrine clearance rate [15] .
Most artemether-lumefantrine studies have only included 1 treatment episode per patient. In areas of high endemicity, recurrent infections are common, and children are often retreated with the first-line ACT [1] , which poses a potential risk of accumulation of lumefantrine. Retreatment has been associated with the selection of lumefantrine-tolerant parasites among those patients with reinfection [16] [17] [18] , linked with single-nucleotide polymorphism (SNP) in pfmdr1 (P. falciparum multidrug resistance gene 1) N86Y, N184F, and D1246Y [19] [20] [21] , as well as pfcrt (P. falciparum chloroquine resistance transporter gene) K76T [22] . The selection of tolerant parasites and safety concerns regarding lumefantrine accumulation represent special challenges to maintaining the efficacy and effectiveness of artemether-lumefantrine.
The aim of this study was to provide efficacy, effectiveness and safety data regarding artemether-lumefantrine treatment in children <5 years of age with uncomplicated falciparum malaria during extended follow-up after both initial treatment and retreatment.
METHODS

Study Area and Patients
The study was conducted from May 2007 through April 2008 in 2 primary health care facilities, Fukayosi and Yombo villages, Bagamoyo District, Tanzania, with high P. falciparum transmission. Study participants were recruited among patients presenting at the study sites for routine care. Inclusion criteria were as follows: fever (axillary temperature >37.5 o C) or fever in the previous 24 h; age <5 years; weight >5 kg; P. falciparum density of 2000-200,000 asexual parasites/lL blood; ability to ingest tablets orally and to attend the clinic for stipulated followup visits; and written informed consent by parents or guardians. Exclusion criteria were as follows: any danger signs (repeated vomiting, unable to drink or feed, convulsion during the present illness, lethargic or unconscious state, and inability to sit or stand); signs of severe malaria [23] ; serious underlying diseases, hemoglobin <5 g/dL; known hypersensitivity to artemetherlumefantrine; or history of antimalarial drug intake within the previous 2 weeks.
The study was approved by the National Institute for Medical Research, Tanzania, and the Regional Ethics Committee, Stockholm, Sweden. Before enrolment, written informed consent was obtained from the parents or guardians.
Study Design, Treatment, and Procedures
This was a randomized, open-label, parallel-group, controlled trial. Patients were randomly assigned supervised or unsupervised artemether-lumefantrine treatment at a 1-to-1 ratio based on a computer-generated randomization list in blocks of 10. Treatment allocation was concealed. Sequentially numbered, opaque sealed envelopes containing the individual treatment allocation (''supervised'' or ''unsupervised'') were prepared from the randomization list. Patients in both groups were to be retreated with artemether-lumefantrine within the same treatment arm in case of recurrent nonsevere P. falciparum infection from day 15 through day 56 after treatment initiation. Patients with severe malaria or general danger signs, treatment failure or recurrent infection within 14 days after initial treatment, or treatment failure or recurrent infection at any time after repeated treatment were withdrawn from the study and treated with quinine.
Artemether-lumefantrine (artemether 20 mg and lumefantrine 120 mg) was administered in a dosage of 1 or 2 tablets for patients weighing 5-14 kg and 15-24 kg, respectively, twice daily for 3 days. Patients assigned supervised treatment were admitted to the facility for 3 days, both at initial treatment and retreatment, and tablets were administered under direct observation. Food-intake or breast milk was encouraged after each drug dose. Patients who vomited within 30 min after treatment received a full replacement dose. Intake of concomitant drugs was recorded.
For patients in the unsupervised group, all artemetherlumefantrine doses were given by the parents or guardians at home after a standardized verbal instruction on dosage frequency and advice to combine treatment with some food or breast milk, to replace the dose if the child vomited within 30 min, and to take the child back to the health facility for rescue medication if .2 replacement doses were needed.
In both treatment groups, parents or guardians were asked to return for review on days 7, 14, 21, 28, 35, 42, 49 , and 56 after initial treatment and on days 7, 14, 21, 28, 35, and 42 after repeated treatment or any other day if the child was ill. Children who did not return for scheduled visits were followed up at home.
Each visit included a clinical assessment (history of clinical symptoms, possible adverse events, concomitant drug consumption, and physical examination). Adverse events were defined as any sign or symptom that occurred or increased in severity after treatment started.
Giemsa-stained thick blood smears were examined at every visit independently by 2 experienced microscopists, and the mean of both readings was taken. In case of discordant results (positive vs negative) or in 2-fold or greater difference in parasite density, a third decisive microscopy reading was performed. In addition, 10% of the blood slides were randomly selected for quality control. Parasite density was quantified by a standard approximation method (40 3 the number of parasites per 200 leucocytes or per 1000 leucocytes for gametocytes). A blood smear was considered to have negative findings if no parasites were seen in 200 high-power fields.
On days 0 and 7 after both initial and repeated treatment, laboratory assessments were performed (hemoglobin levels, blood cell counts, total bilirubin levels, alanine aminotransferase [ALT] levels, c-glutamyl transferase [GGT] levels, and creatinine levels).
Molecular Analysis
We collected 100 lL of blood on filter paper (Whatman 3 MM) at the time of initial and recurrent parasitemia for polymerase chain reaction (PCR) analysis. Distinction between recrudescence and reinfection was performed by stepwise genotyping of the P. falciparum merozoite surface protein 2 (msp2) and 1 (msp1) and glutamate-rich protein (glurp) according to previously described protocols [24] . Recrudescence was defined as at least 1 matching allelic band in all markers between baseline and the day of recurrent parasitemia, whereas reinfections were defined as no matching allelic band for >1 loci. Patients with recurrent parasitemia and no available blood sample or negative PCR results were considered to have uncertain PCR-corrected outcome.
SNPs in the pfcrt K76T and pfmdr1 N86Y were analyzed according to established ApoI restriction enzyme-based PCRrestriction fragment-length polymorphism protocol [25] . Assessment of pfmdr1 gene copy numbers was performed using established TaqMan probe-based real-time PCR protocol (ABI Prism 7000 Sequence Detection System; Applied Biosystems) [26] .
Determination of Lumefantrine Concentrations in the Blood
On day 7 after both initial and retreatment, 100 lL of capillary blood was collected on Whatman 31 ET Chr filter paper pretreated with 0.75 M tartaric acid. Lumefantrine blood concentration was determined using solid-phase extraction and liquid chromatography [27] .
Outcome Measures
Treatment outcomes were classified according to WHO criteria as early treatment failure (ETF), late clinical failure (LCF), late parasitological failure (LPF), and adequate clinical and parasitological response (ACPR) [28] . The clinical and parasitological treatment outcomes were extended from 28 days to 56 and 42 days after initial and retreatment, respectively. ACPR was defined as the absence of parasitemia on day 56 after initial treatment and on day 42 after repeated treatment irrespective of axillary temperature, without any previous occurrence of ETF, LCF, or LPFl. The primary end point was PCR-corrected ACPR by day 56 after initial treatment. Secondary efficacy outcomes included PCR-corrected ACPR at days 14, 28, and 42 after both initial and retreatment. Other secondary end points included protective period against reinfection or recrudescence; potential selection of pfcrt K76T, pfmdr1 N86Y and pfmdr1 gene copy numbers; and day 7 blood lumefantrine concentrations. Safety endpoints included clinical and laboratory adverse events. Laboratory values outside the normal range were classified according to shift tables based on the local laboratory normal ranges and shift tables based on Common Toxicity Criteria (CTC).
Statistical Analysis
Assuming day 56 PCR-corrected parasitological failure rates (recrudescence) of 5% and 15% for supervised and unsupervised artemether-lumefantrine treatment, respectively, we calculated that a minimum of 159 patients would be needed in each group to detect a difference at a 5% significance level and 80% power. Allowing for 10% attrition, a total of 350 patients were required. Data were analyzed with SPSS software, version 17 (SPSS), and Stata software, version 10 (Stata). Statistical significance was set at P < .05.
All efficacy and effectiveness end points were analyzed by survival analysis. Data were censored for patients lost to followup and PCR-confirmed reinfections or uncertain PCR outcome at the time of the last visit. Continuous data were analyzed with Student's t test, and comparison of categorical variables between 
RESULTS
Trial Profile and Baseline Characteristics
A total of 1403 children were screened, of whom 359 were enrolled; 180 were assigned supervised treatment, and 179 were assigned unsupervised treatment (Figure 1 ). Some 258 patients were recruited in Fukayosi, and 101 were recruited in Yombo. The flow of patients through the trial is presented in Figure 1 . The baseline characteristics of the treatment groups are presented in Table 1 .
Parasite and Fever Clearance
Early parasitological responses could only be assessed in the supervised group. Treatment outcome based on WHO criteria are presented in Table 2 . ETFs were uncommon: after initial treatment, 1 patient developed hemolysis with ''coca-cola'' colored urine on day 1 in the supervised group, and after retreatment, 1 patient in each treatment arm developed severe malaria on day 1 ( Table 2) . Parasite genotyping showed that nearly all recurrent infections were attributable to reinfections (Table 2 ). There were 16 recrudescent infections (treatment failures before day 7 and PCR-confirmed recrudescent infections), of which 37.5% (6 of 16) occurred after day 28. PCR-corrected ACPRs were high and were similar in both groups after both initial treatment and retreatment (Table 3) .
The proportion of PCR-confirmed reinfections were similar between the supervised and unsupervised groups after initial treatment (46. (Figure 2a and 2b) .
Prevalence of pfmdr1 N86Y and pfcrt K76T
The frequency of parasites carrying pfmdr1 N86 (in pure form or mixed with 86Y) increased from 66.9% at baseline to 80.0% and 90.3% in recurrent infections after initial treatment and retreatment, respectively (P < .002, Table 4 ). Baseline prevalence of pfcrt K76 in pure form or mixed with 76T was high, (81.5%). However, no significant change in prevalence of pfcrt K76 was observed (Table 4) . No child carried pfmdr1 gene duplications at baseline or in recurrent infections after initial treatment. However, 1 patient with recurrent infection after retreatment carried 2 pfmdr1 copies.
Adverse Events
Artemether-lumefantrine was generally well tolerated after both initial treatment and retreatment. There was no difference in reported adverse events during the first week after treatment initiation (7.3% [26 Table 5) . After day 7, upper respiratory tract infection was the most reported adverse event after both initial treatment and retreatment (Table 5) . Most adverse events were mild or moderate in intensity and were not considered to be related to the study medication.
No deaths occurred. Overall, serious adverse events occurred in 23 children (in 15 after initial treatment and in 8 after retreatment) (Table 5) , all due to severe malaria manifestations during follow-up.
Baseline and day 7 safety laboratory parameters are shown in Table 6 . After initial treatment, mean hemoglobin concentrations decreased significantly from baseline to day 7, but no significant change was observed after retreatment (Table 6) .
Elevated liver function test (LFT) results at baseline were seen in 44% (156 of 359) and 14% (22 of 161) of the patients in the initial treatment and retreatment phase, respectively (Table 1) . However, LFT results were normalized by day 7 except in 5% (19 of 359) and 2% (3 of 161) of patients after initial treatment and retreatment, respectively. In all of these patients, LFT results were only slightly elevated (ie, to CTC Grade 1) and were not considered to be related to the study medication.
Day 7 Blood Lumefantrine Concentrations
On day 7, the median blood lumefantrine concentrations (in ng/ mL) were significantly higher in the supervised treatment group than in the unsupervised treatment group, both after initial treatment (304 vs 194; P < .001) and after retreatment (253 versus 164; P 5 .001) ( Table 7) . A significantly higher proportion of patients with lumefantrine concentrations <280 ng/ mL, which has previously been associated with risk of recrudescence [6] , were observed in the unsupervised treatment group than in the supervised treatment group (P < .02 for all comparisons). However, lumefantrine concentrations did not correlate with different treatment outcomes (recrudescent infection, reinfection, or no parasite reappearance) ( Table 7) .
DISCUSSION
Artemether-lumefantrine was highly efficacious and well tolerated for the treatment of uncomplicated falciparum malaria in children <5 years of age in Tanzania after both initial treatment and retreatment. The PCR-corrected cure rate was high (.90%) in both groups even after extended follow-up. These findings are consistent with previous efficacy studies in sub-Saharan Africa [15, [29] [30] [31] [32] [33] and a recent effectiveness study conducted in Benin [13] . Posttreatment prophylaxis was similar in the treatment groups. However, in this high-transmission area, almost half of the patients had recurrent infections during follow-up, mainly attributable to reinfection. Some of these new infections resulted in clinically severe malaria. Our findings are consistent with other studies from sub-Saharan Africa that have indicated that highly efficacious ACTs like artemether-lumefantrine [31] [32] [33] [34] [35] alone do not provide a long enough recovery period for young children who are of high risk of severe disease and death [36] . The proportion of patients with recurrent parasitemia (late clinical and parasitological failure) was lower after retreatment than after initial treatment, mainly because of a different duration of follow-up.
The influence of extended follow-up beyond 28 days was assessed and, of note, 37.5% of all recrudescent infections were identified beyond 28 days after both initial treatment and retreatment. However, no recrudescence was identified beyond 42 days, which is similar to a recent report from Uganda [33] indicating 42-days of follow-up to be optimal for assessment of PCR-corrected efficacy or effectiveness of artemether-lumefantrine treatment.
Our findings confirm the safety and tolerability of artemether-lumefantrine treatment after 1 treatment episode [15, 37] . Interestingly, our data indicate that artemetherlumefantrine is equally safe and tolerable after retreatment. Previous concerns regarding the potential accumulation of lumefantrine after retreatment could thus not be confirmed. This is reassuring, because the real-life situation is that many African children experience .1 episode of clinical malaria during relatively short intervals. The median day-7 lumefantrine concentrations were significantly lower in the unsupervised treatment group than in the supervised treatment group, reflecting lower adherence to either the drug or dietary advice. However, supervised drug administration did not warrant adequate lumefantrine concentrations in all patients; approximately half of the supervised patients had concentrations <280 ng/mL. This finding is consistent with previous studies from Uganda [14] , where age <5 years and a decrease in the lumefantrine dosage were associated with low lumefantrine concentrations [14] . However, these findings did not affect therapeutic responses in our study; PCR-corrected cure at >42 days was achieved even in patients with low concentrations (<280 ng/mL), suggesting that the local P. falciparum population was highly susceptible to lumefantrine. The generally lower lumefantrine concentrations observed in the unsupervised group, however, are still a concern, which may, in the future, potentially compromise the treatment outcome after uncontrolled drug intake. Therefore, we believe it is important to include analysis of drug susceptibility in vitro, in addition to day 7 lumefantrine concentrations, in future surveillance of artemether-lumefantrine efficacy and effectiveness in vivo.
A concern with ACTs in high-transmission areas is that the slow clearance of the partner drugs may facilitate selection of tolerant or resistant parasites [16] [17] [18] . Our results indicate significant selection of pfmdr1 N86 after both initial treatment and retreatment with artemether-lumefantrine. These results are similar to those of previous studies [19] [20] [21] and provide evidence for in vivo selection of pfmdr1 N86 allele, which is associated with decreased lumefantrine susceptibility. However, our data do not suggest that amplification of pfmdr1 is a common phenomenon in the study area, because only 1 sample with 2 pfmdr1 copies was detected. Still, the selection of pfmdr1 N86, which is closely linked to pfmdr1 duplication in Southeast Asia, calls for close future molecular surveillance of the local P. falciparum population. We did not find a statistically significant selection of pfcrt K76, as in our recent report from the same study site [22] . This may be attributable to the high prevalence of pfcrt K76 at baseline (81.5%).
In conclusion, artemether-lumefantrine treatment was highly efficacious in Tanzanian children <5 years of age with uncomplicated falciparum malaria, even with unsupervised administration, despite significantly lower lumefantrine blood concentrations, compared with those in children who received supervised treatment, and it was well tolerated and safe both after initial treatment and retreatment. However, the high rates of reinfection observed during both post-treatment periods and the selection of genotypes associated with tolerance and resistance to lumefantrine are concerns that call for close future surveillance of artemether-lumefantrine efficacy and effectiveness in Africa.
